Design Therapeutics (DSGN) Competitors $3.93 -0.31 (-7.31%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN vs. RCUS, NRIX, CMRX, CDMO, OCS, ELVN, GYRE, AVDL, VIR, and RCKTShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), Chimerix (CMRX), Avid Bioservices (CDMO), Oculis (OCS), Enliven Therapeutics (ELVN), Gyre Therapeutics (GYRE), Avadel Pharmaceuticals (AVDL), Vir Biotechnology (VIR), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry. Design Therapeutics vs. Arcus Biosciences Nurix Therapeutics Chimerix Avid Bioservices Oculis Enliven Therapeutics Gyre Therapeutics Avadel Pharmaceuticals Vir Biotechnology Rocket Pharmaceuticals Design Therapeutics (NASDAQ:DSGN) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking. Which has more volatility and risk, DSGN or RCUS? Design Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Does the MarketBeat Community prefer DSGN or RCUS? Arcus Biosciences received 187 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 65.45% of users gave Arcus Biosciences an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformDesign TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% Arcus BiosciencesOutperform Votes19765.45% Underperform Votes10434.55% Which has stronger valuation & earnings, DSGN or RCUS? Design Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Design Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$66.86M-$0.88-4.82Arcus Biosciences$258M3.43-$307M-$3.10-2.71 Do analysts rate DSGN or RCUS? Design Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 88.68%. Arcus Biosciences has a consensus target price of $28.38, indicating a potential upside of 237.60%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to DSGN or RCUS? In the previous week, Arcus Biosciences had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Arcus Biosciences and 4 mentions for Design Therapeutics. Arcus Biosciences' average media sentiment score of 0.59 beat Design Therapeutics' score of 0.44 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DSGN or RCUS more profitable? Design Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Design Therapeutics' return on equity of -18.01% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -18.01% -17.38% Arcus Biosciences -102.66%-45.59%-22.38% Do institutionals and insiders hold more shares of DSGN or RCUS? 56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 31.2% of Design Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryArcus Biosciences beats Design Therapeutics on 11 of the 18 factors compared between the two stocks. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.68M$6.59B$5.40B$7.70BDividend YieldN/A3.20%5.44%4.32%P/E Ratio-4.997.0522.1918.31Price / SalesN/A273.45401.66107.05Price / CashN/A65.6738.2034.62Price / Book0.856.506.854.25Net Income-$66.86M$142.50M$3.20B$247.51M7 Day Performance21.14%8.32%5.91%6.33%1 Month Performance-7.63%-5.61%-4.20%-3.33%1 Year Performance12.77%0.11%18.07%5.15% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics1.6499 of 5 stars$3.93-7.3%$8.00+103.6%+16.2%$223.08MN/A-4.6240News CoverageRCUSArcus Biosciences2.1309 of 5 stars$7.68-2.5%$30.25+293.9%-45.5%$807.46M$258M-2.44500Analyst ForecastGap DownNRIXNurix Therapeutics2.3783 of 5 stars$10.55+3.0%$30.44+188.6%-16.2%$804.29M$56.42M-3.65300Positive NewsCMRXChimerix2.7886 of 5 stars$8.55-0.1%$8.53-0.1%N/A$801.56M$212,000.00-9.0990Upcoming EarningsAnalyst ForecastNews CoverageCDMOAvid Bioservices0.7169 of 5 stars$12.50+0.1%$12.25-2.0%+82.9%$799.18M$139.91M-5.23320High Trading VolumeOCSOculis2.0255 of 5 stars$18.12-0.8%$30.25+66.9%+50.7%$797.71M$980,000.00-9.392ELVNEnliven Therapeutics2.1803 of 5 stars$16.22-1.9%$40.33+148.7%+4.6%$794.85MN/A-8.5450GYREGyre TherapeuticsN/A$8.40-5.4%N/A-43.2%$786.34M$105.76M168.0040AVDLAvadel Pharmaceuticals1.9077 of 5 stars$7.96-0.9%$19.88+149.7%-51.3%$775.93M$169.12M-10.0870VIRVir Biotechnology2.7455 of 5 stars$5.61+2.0%$33.57+498.4%-21.8%$769.37M$63.71M-1.43580Upcoming EarningsNews CoverageRCKTRocket Pharmaceuticals4.6531 of 5 stars$7.17+13.3%$43.00+499.7%-68.6%$764.54MN/A-2.61240News CoveragePositive NewsHigh Trading Volume Related Companies and Tools Related Companies RCUS Alternatives NRIX Alternatives CMRX Alternatives CDMO Alternatives OCS Alternatives ELVN Alternatives GYRE Alternatives AVDL Alternatives VIR Alternatives RCKT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DSGN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
